Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00589602 · OUTCOME

Number of Participants With Duration of Absolute Neutropenia

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases · Source last updated 2017-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
D+100 from transplant

Groups in this outcome

T-Cell Depletion Transplant

peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg. cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day -5 and Day -4 tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
T-Cell Depletion Transplant12

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
T-Cell Depletion Transplant10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
groups
  1. description
    peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg. cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day -5 and Day -4 tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days
    id
    OG000
    title
    T-Cell Depletion Transplant
param Type
NUMBER
reporting Status
POSTED
time Frame
D+100 from transplant
title
Number of Participants With Duration of Absolute Neutropenia
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice